TriSalus swings to Q1 FY26 profit of $1.5 million; revenue falls 2.9% to $8.9 million
PUBT · 6h ago
Share
Listen to the news
- Trisalus Life Sciences posted Q1 revenue of $8.9 million, down 2.9% year over year.
- Net income available to common stockholders swung to $1.5 million, with basic EPS at $0.03.
- Operating loss widened to $8.4 million, while gross margin rose 2.5 percentage points to 86.2%.
- Cash and cash equivalents climbed to $56.6 million following a $46 million equity raise.
- 2026 revenue guidance was revised to $54 million-$57 million, citing commercial expansion and timing of FDA clearance for TriNav Advance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605121601BIZWIRE_USPR_____20260512_BW970102) on May 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved